Shielded Living Therapeutics Cell for Rare Blood Disorders - Medical / Health Care - Clinical Services
Rare blood disorders are a group of rare genetic disorders where the blood does not clot properly. Existing therapies for blood disorders place a high burden on patients and caregivers, requiring infusions as often as multiple times each week over a patient’s lifetime.
Most popular related searches
At Sigilon, we recognize this burden and understand that living or caring for someone with a rare blood disorder is more than just an infusion. It’s a caregiver of a young child learning to recognize the signs of a bleed or an adult having trouble with venous access or having arthritis and limited joint mobility as a result of years of infusions and peaks and troughs of factor.
Sigilon initiated a Phase 1/2 study in previously treated male patients with severe or moderately severe hemophilia A. The study is designed to evaluate the safety, tolerability, and preliminary efficacy of SIG-001 in adult male patients with severe or moderately severe hemophilia A without inhibitors. This trial remains on clinical hold and is not actively recruiting patients.